Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease

Figures & data

Table 1. Subject demographics and treatment information.

	CD		UC		Non-IBD
Cohort	STL	CBG	STL	CBG	STL	CBG
Number of patients	30	3	14	11	30	9
Number of specimens	62	8	26	26	30	11
% Male	33.3	33.3	57.1	63.6	33.3	55.5
Age	43.2 ± 14.8	46.0 ± 11.0	49.9 ±15.5	38.5 ± 14.2	50 ± 15.5	44.9 ± 11.6
BMI (n)	25.7 ± 5.5 (28)	NA	29.2 ± 7.4^## (14)	NA	23.6 ± 5.2 (29)	NA
Race		100		100		100
% Caucasian	93.3 **		92.9		66.7
% African American	6.7		7.2		20.0
% Other	0.0 **		0.0		13.3
Longitudinal (n)	20	1	6	6	0	1
Treatment^#
% Steroids (oral/IV)	26.7	66.7	20	72.7	0	0
% Vedolizumab	43.3	0	16.7	0	0	0
% TNFα inhibitors	36.7	0	10	0	0	0
% 5-ASAs	30	0	43.3	90.9	0	0
% Purine analogs	43.3	33.3	16.7	36.4	0	0
% Other immunomod^	10	33.3	16.7	27.3	0	0
% Antibiotics	13.3	33.3	3.3	9.4	7.2	0

Date presented as ± mean.

^#Treatment information for the second sample collected for subjects with longitudinal sampling. **CD vs Non-IBD; ^##UC vs Non-IBD

Figure 1. Increased Ig-bound fecal bacteria in IBD patients.

Figure 2. Percentage of IgA⁺ and IgG⁺ fecal bacteria correlate with CD activity.

Figure 3. Only IgG+ fecal bacteria percentage correlates with UC activity.

Figure 4. Characteristics of IgA and IgG-bound commensal bacteria.

Figure 5. Taxa of Ig-enriched bacteria in IBD are often associated with oral pharynx.

Figure 6. Bacterial OTUs enriched in IBD.